FDA Grants Rare Pediatric Disease Designation to LGMD Type 2E
The FDA has granted Rare Pediatric Disease Designation to Myonexus Therapeutics for its MYO-101, which is an AAV-based gene therapy for the treatment of limb girdle muscular dystrophy (LGMD) type 2E.
FDA Grants Orphan Drug Designation to Sarconeos for Duchenne Muscular Dystrophy (DMD)
FDA grants orphan drug designation to Sarconeos for Duchenne muscular dystrophy (DMD).
MS Therapy Approved by FDA
Late Friday afternoon, Novartis announced that the U.S. FDA approved fingolimod (Gilenya) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older.
Sarepta and Invitae Expand Partnership for DMD Research
This morning, it was announced that Invitae Corporation and Sarepta Therapeutics will be expanding its partnership to continue assisting clinicians in identifying patients with Duchenne muscular dystrophy (DMD).
Cytokinetics and the ALS Association Renew Partnership to Fight ALS
Cytokinetics, Incorporated and The ALS Association continue their partnership in an effort to fight ALS.
FDA Grants Fast Track Designation to FSHD Therapy
This morning, Acceleron Pharma announced that the US FDA has granted Fast Track designation to ACE-083 for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD).
Capricor Initiates HOPE-2 Clinical Trial of Duchenne Drug
This morning, Capricor Therapeutics, Inc. announced that the HOPE-2 clinical trial has been initiated at UC Davis Medical Center in Sacramento, CA.
Is New Type 1 SMA Treatment in Sight?
Data from Type 1 spinal muscular atrophy (SMA) treatment suggests efficacy and tolerability.
24-Week Analysis from PhaseOut DMD Presented at AAN
At the 70
AAN Annual Meeting this morning Summit Therapeutics plc presented new 24-week interim data from PhaseOut DMD, its Phase 2 trial of ezutromid in Duchenne.
First Patient Enrolled in Phase 3 Trial of Firdapse in MuSK Antibody Positive Myasthenia Gravis
The first patient was enrolled in a Phase 3 clinical trial of amifampridine phosphate (Firdapse) in patients with mmuscle-specific kinase (MuSK) antibody positive myasthenia gravis (MuSK-MG).
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.